Reply to P. Niravath et Al.
暂无分享,去创建一个
[1] C. Osborne,et al. Aromatase inhibitor adverse effects: are we sweeping them under the rug? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Gelmon,et al. Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Cuzick,et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.
[4] R. Chlebowski,et al. Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings , 2014, Cancer Prevention Research.
[5] Lang Li,et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Tangoku,et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia , 2011, BMC Cancer.
[7] Karen A Gelmon,et al. Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.
[8] Yusuke Nakamura,et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.